Relmada Therapeutics, Inc. (RLMD) stock forecast and price target
Price $4.21 · data as of November 13, 2026
12-month price target
Average target$10.75
Upside / downside+155.3%
Analysts4
ConsensusStrong buy
Low $9.00Average $10.75High $12.00
Gold marker: average target · white marker: today’s price ($4.21)
Analyst ratings
Strong buy 1Buy 3Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.41 | +62.8% | $0 |
| Next fiscal year ends December 31, 2027 | $-0.41 | +0.0% | $0 |
| Next quarter ends December 31, 2026 | $-0.12 | — | $0 |
| Quarter after ends March 31, 2027 | $-0.14 | — | $0 |
Consensus of the analysts covering Relmada Therapeutics, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Frequently asked questions
What is the Relmada Therapeutics stock price target?
The average 12-month target from 4 analysts is $10.75, 155.3% above the current price of $4.21 Targets range from $9.00 to $12.00.
Is Relmada Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 3 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Relmada Therapeutics expected to earn?
Analysts expect EPS of $-0.41 for the fiscal year ending December 31, 2026 and $-0.41 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.